Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 3 1

Status

Recruiting 3

Sponsor Class

OTHER 57NIH 48NETWORK 8INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 2Head & Neck 1Genitourinary 1Breast 1

Conditions

Triple Negative Breast Neoplasms 1Prostatic Neoplasms 1Lung Neoplasms 1Head and Neck Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 290Carboplatin 219Gemcitabine 150Cisplatin 150Paclitaxel 149Pemetrexed 119Bevacizumab 117Docetaxel 101Oxaliplatin 83durvalumab 80Fluorouracil 80Nivolumab 77Dexamethasone 77Cyclophosphamide 76atezolizumab 73130-nm albumin-bound paclitaxel 71Fulvestrant 69Capecitabine 69Injections 64Leucovorin 63Cetuximab 58Rituximab 56Lenalidomide 52fludarabine 50venetoclax 45Prednisone 44Irinotecan 42Letrozole 40ribociclib 38tislelizumab 37

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × X-Rays × 90 days × Clear all
NCT07581184 2026-05-12

BActinium-1

Aktis Oncology, Inc.

Phase 1 Recruiting
138 enrolled
Genitourinary

Prostatic Neoplasms

NCT07020117 2026-04-21

A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors

Aktis Oncology, Inc.

Phase 1 Recruiting
150 enrolled
BreastHead & NeckThoracic

Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms, Triple Negative Breast Neoplasms

NCT07499674 2026-03-30

VISUALIZE-2

Vergent Bioscience, Inc.

Phase 3 Recruiting
132 enrolled
Thoracic

Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡